跳至主要内容
临床试验/NCT02365740
NCT02365740Unknown不适用

Postprandial Blood Glucose Control and Gastric Emptying in Patients With Type 1 Diabetes: Pathogenetic Factors, Clinical Relevance and Possible Therapeutic Options

Federico II University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2014年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
80
试验地点
1
主要终点
gastric emptying measure

研究概览

简要总结

This study evaluates the prevalence of gastric emptying (GE) in type 1 diabetic patients (DM1) free of chronic complications in comparison with a group of healthy control subjects. The investigators will also assess the relationship between GE and glucose control (HbA1c, postprandial glucose variability), gut peptide hormones (GLP-1, GIP, and ghrelin), and gastrointestinal symptoms.

In addition, in patients with delayed GE the investigators will investigate the effect of "tailored" pre-prandial insulin bolus administered by means of insulin pump in reducing postprandial glucose variability, evaluated through continuous glucose monitoring system.

详细描述

Diabetic patients with a delayed GE will be studied in 2 separate occasions in euglycemic condition and under CGM. On both occasions, they will have to take a standard meal poor of lipids (rice 60 g; yellow squash 200 g; extra virgin olive oil 7 g; adult veal lean cuts 90 g; bananas 180 g; ordinary bread 75 g).

On the first occasion pre-prandial insulin will be administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load.

On the second occasion the amount of pre-prandial insulin will be the same as the first one test but fractioned into a double-wave bolus. The "tailored" insulin bolus will be defined according to the individual pattern of GE, as follows:

  • GE T1/2 121-180 min= 60% as bolus + 40% during following 2 h
  • GE T1/2 >180 min= 40% as bolus + 60% during following 4 h Glycemic variability will be assessed by the means of Continuous Glucose Monitoring System and the following indexes of glucose variability will be calculated: number of hypoglycemic events, number of hyperglycemic events, standard deviation of glycemia, glycemia variation coefficient, mean range of daily glycemia, interquartile range, M value, mean amplitude of glycemic excursions (MAGE), low blood glucose index (LBGI), high blood glucose index (HBGI).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Use of insulin pump;
  • Disease duration ≥ 3 years.

排除标准

  • Presence of chronic complications of DM (including cardiovascular autonomic neuropathy);
  • BMI ≥ 30 kg/m2;
  • Presence of chronic diseases other than DM1;
  • Diseases that interfere with GE;
  • Medications that interfere with blood glucose homeostasis (except insulin) and GE.

研究组 & 干预措施

Controls

Sham Comparator

gastric emptying test gut hormones determination

干预措施: gut hormones determination (Other)

Cases

Experimental

gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus

干预措施: gastric emptying test (Other)

Cases

Experimental

gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus

干预措施: gut hormones determination (Other)

Cases

Experimental

gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus

干预措施: Continuous Glucose Monitoring (Other)

Cases

Experimental

gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus

干预措施: Insulin single bolus (Drug)

Cases

Experimental

gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus

干预措施: Insulin double-wave bolus (Drug)

Controls

Sham Comparator

gastric emptying test gut hormones determination

干预措施: gastric emptying test (Other)

结局指标

主要结局

gastric emptying measure

时间窗: 4 hours

次要结局

  • gut hormones dosage(3 hours)
  • Continuous Glucose Monitoring(7 days)
  • postprandial glucose variability after single insulin bolus(3 hours)
  • postprandial glucose variability after double-wave insulin bolus(3 hours)

研究者

发起方
Federico II University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Brunella Capaldo

MD

Federico II University

研究点 (1)

Loading locations...

相似试验